Comparative Pharmacology
Head-to-head clinical analysis: EPIDIOLEX versus VIGABATRIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EPIDIOLEX versus VIGABATRIN.
EPIDIOLEX vs VIGABATRIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cannabidiol is a cannabinoid with anticonvulsant properties. Its exact mechanism is unknown but may involve modulation of neuronal calcium channels, inhibition of adenosine reuptake, and agonism of 5-HT1A receptors.
Irreversibly inhibits GABA transaminase, increasing brain GABA levels.
Initial 2.5 mg/kg orally twice daily; after 1 week, increase to 5 mg/kg twice daily; may titrate to 10 mg/kg twice daily based on tolerability and efficacy. Maximum dose: 20 mg/kg daily.
Adults: 500 mg orally twice daily; may increase by 500 mg/day every 7 days up to 1500 mg twice daily. For refractory complex partial seizures, maximum 3000 mg/day.
None Documented
None Documented
Clinical Note
moderateVigabatrin + Venlafaxine
"The risk or severity of adverse effects can be increased when Vigabatrin is combined with Venlafaxine."
Clinical Note
moderateVigabatrin + Nefazodone
"The risk or severity of adverse effects can be increased when Vigabatrin is combined with Nefazodone."
Clinical Note
moderateVigabatrin + Stiripentol
"The risk or severity of adverse effects can be increased when Vigabatrin is combined with Stiripentol."
Clinical Note
moderateVigabatrin + Clomipramine
The terminal elimination half-life of cannabidiol following oral administration is approximately 56-61 hours in healthy volunteers and 31-40 hours in patients with epilepsy. This long half-life supports once-daily dosing for chronic conditions.
5-8 hours in young adults; 12-17 hours in elderly; prolonged with renal impairment.
Cannabidiol (CBD) is primarily eliminated via fecal excretion (approximately 73-94% of the dose) as unchanged drug and metabolites, with renal excretion accounting for less than 5% of the dose. Biliary excretion contributes to fecal elimination.
Renal: ~80% unchanged in urine; fecal: <5%.
Category C
Category A/B
Anticonvulsant
Anticonvulsant
"The risk or severity of adverse effects can be increased when Vigabatrin is combined with Clomipramine."